Biocartis Appoints Mike Kreitzinger as Senior VP of Global Business Development
Biocartis, a trailblazer in molecular diagnostics, is excited to introduce Mike Kreitzinger as the new Senior Vice President of Global Business Development. His effective date for this pivotal role was announced recently. Kreitzinger will spearhead efforts in sourcing partnerships and executing strategies that drive the company’s growth in the competitive field of precision oncology.
Expertise to Drive Commercial Growth
With over 25 years of experience in clinical diagnostics, Kreitzinger's diverse background blends business acumen with scientific expertise. He has previously excelled as the Senior Director of Clinical Strategy and Partnerships at Illumina, where he played a key role in aligning clinical strategies with partnership goals. His leadership in the genomics space prepares him well to help Biocartis enhance its global outreach and embed its innovative solutions in oncology practices.
Creating Strategic Alliances
In his new position, Kreitzinger will concentrate on developing and nurturing strategic alliances that can propel Biocartis to new heights. His leadership aims to significantly improve the integration of the company’s products into the healthcare ecology, providing timely results for patients in need of rapid oncology biomarker testing.
Joining a Visionary Team
Kreitzinger expressed his enthusiasm for being part of Biocartis, stating, 'I am honored to join the stellar team at Biocartis as we advance the mission of providing rapid oncology biomarker results. Cancer is a disease of the genome, and rapid assessment enables providers the answers they need when they need them.' His commitment to accelerating real-world applications of molecular diagnostics will significantly impact patient care.
Commitment to Cancer Care
Biocartis has established itself as a leader in the diagnostics field, with its proprietary Idylla™ Platform allowing healthcare professionals to receive molecular biomarker results in just three hours. This expedited process supports personalized therapy decisions for patients battling various cancers, including lung, skin, and breast cancer, among others. The company’s continual evolution aligns with the critical patient need for fast and accurate diagnosis and treatment.
Expanding Digital Presence
The appointment of Kreitzinger comes at a time when Biocartis is also enhancing its digital presence. The company remains dedicated to facilitating easier access to vital information related to cancer biomarkers and treatment options through its platforms. With a strong push towards innovation and collaboration, Biocartis is poised for substantial growth in the coming years.
Future Endeavors and Goals
As Kreitzinger steps into his role, he is set to leverage his extensive experience to cultivate partnerships that will expand the reach of Biocartis's offerings. His actions will be pivotal in guiding the company's strategic direction, ensuring that their cutting-edge solutions are integrated into clinical practices effectively.
Connect with Biocartis
Biocartis invites interested parties to learn more about the company and its offerings. Based in Belgium, with a vital presence in the U.S., the company remains a key player in molecular diagnostics, aiming to bring rapid and reliable diagnostic solutions to the forefront of cancer care. For additional information, contact Biocartis NV or Biocartis US Inc.
Frequently Asked Questions
What is Biocartis?
Biocartis is a molecular diagnostics company focused on providing rapid and precise testing solutions to enhance cancer patient care.
Who is Mike Kreitzinger?
Mike Kreitzinger is the newly appointed Senior Vice President of Global Business Development at Biocartis, bringing extensive experience in the diagnostics sector.
What role does Kreitzinger have at Biocartis?
Kreitzinger is responsible for developing and executing strategies to foster partnerships and drive commercial growth within the precision oncology market.
What technology does Biocartis utilize?
Biocartis employs the Idylla™ Platform for rapid molecular biomarker testing, providing results within three hours.
Why is rapid testing important in oncology?
Rapid testing allows healthcare providers to make timely decisions regarding treatment, which is crucial for effective cancer management.
